Trial Profile
Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Sarilumab (Primary)
- Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms STRIKESARS
- 10 Apr 2022 Status changed from recruiting to completed.
- 14 Dec 2020 Planned primary completion date changed from 30 Nov 2020 to 30 Dec 2020.
- 23 Apr 2020 New trial record